A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2016
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Voxilaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 17 Apr 2016 Pooled analysis of 2 studies - GS-US-367-1168 and GS-US-367-1169 (n=130) were presented at The International Liver Congress™ 2016.
- 16 Apr 2016 Results published in a Gilead Sciences media release.
- 16 Apr 2016 Combined results from this and another phase II trial (CTP 700254491) presented at the The International Liver Congress 2016, according to a Gilead Sciences media release.